The newly established role as COO includes responsibilities such as coordination of management functions, legal issues, compliance and supply chain management. Linda Glimberg will take up her position as COO on June 1, 2024 and Niklas Adenborg will take up his position as CFO on July 1, 2024.

”Xspray Pharma is building up momentum this year in order to transform from a research and development company to a commercial life science company. I am pleased to be able to strengthen the management by the internal recruitments of two highly competent individuals that will take on greater responsibilities as we now enter into this new and exciting phase for the company,” says Xspray Pharma’s CEO Per Andersson.

Niklas Adenborg has extensive finance and auditing experience, and has previously been auditor at KPMG. Niklas was employed by Xspray Pharma in 2019 and currently holds the position as Finance Director. Linda Glimberg has extensive legal experience including in relation to life science. Linda has during the past few years managed her own consulting business focusing on business law, compliance and the provision of structure and strategic advice  to small and mid-sized life science companies. She has broad prior experience from different listed companies and sectors, including the role as VP & Corporate Counsel at Husqvarna.

The current Interim CFO will be leaving the company when his assignment has been completed.